Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Immunitybio Inc

IBRX
Current price
2.47 USD 0 USD (0.00%)
Last closed 2.72 USD
ISIN US45256X1037
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 179 693 568 USD
Yield for 12 month -50.00 %
1Y
3Y
5Y
10Y
15Y
IBRX
21.11.2021 - 28.11.2021

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California. Address: 3530 John Hopkins Court, San Diego, CA, United States, 92121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

11.25 USD

P/E ratio

Dividend Yield

Current Year

+14 745 000 USD

Last Year

+622 000 USD

Current Quarter

+7 552 000 USD

Last Quarter

+6 106 000 USD

Current Year

+14 745 000 USD

Last Year

+622 000 USD

Current Quarter

+7 552 000 USD

Last Quarter

+6 106 000 USD

Key Figures IBRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -326 628 992 USD
Operating Margin TTM -918.98 %
Price to Earnings
Return On Assets TTM -48.48 %
PEG Ratio
Return On Equity TTM
Wall Street Target Price 11.25 USD
Revenue TTM 14 745 000 USD
Book Value -0.57 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 5 333.10 %
Dividend Yield
Gross Profit TTM 14 745 000 USD
Earnings per share -0.62 USD
Diluted Eps TTM -0.62 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics IBRX

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History IBRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor
Payout Ratio
Last Split Date

Stock Valuation IBRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 171.86
Price Sales TTM 147.83
Enterprise Value EBITDA -8.99
Price Book MRQ

Financials IBRX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators IBRX

For 52 weeks

2.28 USD 10.53 USD
50 Day MA 2.99 USD
Shares Short Prior Month 59 544 447
200 Day MA 3.87 USD
Short Ratio 10.24
Shares Short 63 183 105
Short Percent 19.85 %